Sorrento Therapeutics CEO and leadership

Dr. Ji’s extensive knowledge of the industry in which we operate, as well as his unique role in our day-to-day operations as our Chief Executive Officer and President, allows him to bring to our board of directors a broad understanding of the operational and strategic issues we face. Dr. Ji also served as Sorrento’s Secretary from September 2009 to June 2011, Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji is the holder of several issued and pending patents in the life science field and is the sole inventor of Sorrento Inc.’s intellectual property covering the G-MAB® library technology. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.

Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016.

Dr. Ji’s extensive knowledge of the industry in which we operate, as well as his unique role in our day-to-day operations as our Chief Executive Officer and President, allows him to bring to our board of directors a broad understanding of the operational and strategic issues we face. Dr. Ji also served as Sorrento’s Secretary from September 2009 to June 2011, Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji is the holder of several issued and pending patents in the life science field and is the sole inventor of Sorrento Inc.’s intellectual property covering the G-MAB® library technology. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.

Dr. Ji’s extensive knowledge of the industry in which we operate, as well as his unique role in our day-to-day operations as our Chief Executive Officer and President, allows him to bring to our board of directors a broad understanding of the operational and strategic issues we face. Dr. Ji also served as Sorrento’s Secretary from September 2009 to June 2011, Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji is the holder of several issued and pending patents in the life science field and is the sole inventor of Sorrento Inc.’s intellectual property covering the G-MAB® library technology. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.

Excellent track record of transformation and creating innovative companies with documented success in product development and commercialization of some of today’s most recognized pharmaceutical brands. Co-founder, CEO and President of Semnur Pharmaceuticals since its inception in 2013 and CEO Scilex since 2019. Board director for multiple innovative biotechs. A seasoned life science executive and Board director with extensive accomplishments at Bristol-Myers Squibb, Roche, PDL Biopharma, Sorrento, Pfizer/Upjohn, Scilex and start-ups Elevation and Semnur Pharmaceuticals.Over 25 year industry success in leading product development & commercializing innovative therapies. Managed late stage product development and commercialization for Rituxan, Pegasys, Abilify launch and lifecycle teams each reached over $2 billion sales. Led business development, marketing, franchise management and operational teams at Roche, BMS, and PDL Biopharma. Broad Expertise in collaborations & business development in variety of therapeutic franchises: Oncology, Respiratory, Immunology, Infectious Disease, Virology, CNS, Autoimmune, Inflammation, CV, and Pain therapy areas.Milestones: Negotiated and completed successful business transactions - $350m Merger of Scilex and Semnur Pharma- $1.2 billion collaboration PDL/BMS results in Empliciti approval for Multiple Myeloma (Top 5 Antibody Mega Deals, BioCentury 2009)- $800 million PDL-Biogen Idec collaboration resulting in Zinbryta approval for MS- $430 million Elevation Pharma sale to Sunovion (Top 10 Acquisitions of VC companies, WSJ 2012) leading to Lonhala approval for COPD- $200 million sale of IV Busulfex by PDL to Otsuka - $200 million sale of CV products to EKR- $300 million PDL asthma and transplant collaborations with Roche- Sorrento acquisition of Scilex for ZTlido- BMS $250m global license of Otsuka/Abilify Global deal-maker with proven partnering and negotiation skills, strong track record of closing licensing deals with cumulative deal values of |$1 billion. Honored with numerous company awards, including BMS President’s Award.